Berlin, Germany, and New York, NY—As of October 29, 2024, Aignostics, an AI-based leader in precision pathology, raised $34 million in series B funding. The new funding core areas focus on clinical research and diagnostics of biopharmaceuticals.
The new funding will support further expansion of Aignostics’ activities in the US and the growth of the Aignostics U.S. Company which works with Mayo Clinic to develop AI pathology models for translational research, tumor profiling, and drug development.
ATHOS acted as the round leader; Mayo Clinic, HTGF, previous investors Wellington Partners, and Boehringer Ingelheim Venture Fund have increased participation in this round.
This investment round has elevated total funding of Aignostics to more than $ 55 million and shows continuously growing investor interest in Aignostic high precision AI models and integration of data streams.
Aignostics intends to develop AI solutions for pathology that can be implemented by biopharma clients for an array of diagnostic and therapeutical strategies out of the box.
‘Fundamentally, Aignostics is a global Machine Learning enterprise with the rare touch of impressive vision in machine learning’ – Julian Zachmann, ATHOS. Aignostics’ AI solutions that are designed for biomarker analysis, clinical research, and other complexities will be beneficial to biopharma clientele.
Jim Rogers, who is the CEO of Mayo Clinic Digital Pathology Solutions, stated,
“AI in conjunction with digital pathology has the potential to transform the world of personalized health care.”
For its part, Aignostics is also introducing a model called
“RudolfV” as its foundation model that allows inexpensive and flexible algorithms in real diagnostics.
Viktor Matyas, CEO and Co-founder of Aignostics, says that,
“This year is a turning point for us. Such funding provides an opportunity for us to create algorithms in order to start a new age of adjustable AI in the field of computational pathology.”
With AI lowering the time frame for data analysis and its application in the target healthcare for the individual patient, Aignostics’ AI-woven pathology solutions are prepared to be pioneered features in the fast-growing niche of precision medicine.
What is your reaction?
